Retractable Technologies Wins Permanent Injunction Against OMI March 09, 2010 by Astrid Fiano, DOTmed News Writer Retractable Technologies, Inc. of Little Elm, TX, has won a judgment against Occupational & Medical Innovations, Ltd. (OMI) of Slacks Creek, Australia. The injunction follows a jury verdict that OMI had misappropriated Retractable's trade secrets and infringed Retractable's U.S. Patent (No. 6,572,584).
According to court documents, U.S. District Judge Leonard Davis ordered that Retractable shall recover from OMI damages in the sum of $2,990,098 (the sum found by the jury plus damages based on OMI's sales since July 2009), and prejudgment interest in the amount of $163,477, for a total amount of $3,153,575. In addition, OMI has been permanently enjoined as of March 4 from the making, selling, offering, or importing of the OMI syringes that infringed the patent until its expiration.
The patent at issue involves a safety syringe marketed by Retractable under the name VanishPoint. The VanishPoint syringe offers reliable protection against blood-borne pathogens due to syringe reuse or due to accidental needle-stick injuries as the syringe automatically retracts the needle back inside the syringe body when the plunger is fully depressed following medicine delivery. Retractable had accused OMI of redesigning its own syringes using information about the VanishPoint product, confidential information allegedly obtained from Double Dove, a company in China under contract to Retractable for manufacture. http://www.dotmed.com/news/story/11913/
ICU Price at posting:
72.5¢ Sentiment: None Disclosure: Not Held
